Parexel International Corp. (NASDAQ:PRXL) – Jefferies Group lifted their Q3 2017 earnings estimates for Parexel International Corp. in a research note issued on Tuesday. Jefferies Group analyst D. Windley now expects that the firm will earn $1.05 per share for the quarter, up from their previous forecast of $1.02. Jefferies Group has a “Hold” rating and a $64.00 price target on the stock. Jefferies Group also issued estimates for Parexel International Corp.’s Q4 2017 earnings at $1.12 EPS.

Several other analysts have also recently issued reports on PRXL. Citigroup Inc. boosted their price objective on shares of Parexel International Corp. from $74.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, August 5th. Deutsche Bank AG upped their price target on shares of Parexel International Corp. from $65.00 to $71.00 and gave the stock a “hold” rating in a research report on Friday, August 5th. Evercore ISI reaffirmed a “buy” rating and set a $78.50 price target (up from $71.00) on shares of Parexel International Corp. in a research report on Friday, August 5th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Parexel International Corp. in a research report on Tuesday, September 27th. Finally, Zacks Investment Research raised shares of Parexel International Corp. from a “sell” rating to a “hold” rating in a research report on Wednesday, October 19th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $66.70.

Earnings History and Estimates for Parexel International Corp. (NASDAQ:PRXL)

Shares of Parexel International Corp. (NASDAQ:PRXL) remained flat at $58.16 during trading on Thursday. The stock had a trading volume of 1,083,520 shares. The firm has a market cap of $3.10 billion, a P/E ratio of 18.64 and a beta of 0.91. Parexel International Corp. has a 52-week low of $51.16 and a 52-week high of $71.13. The firm has a 50 day moving average of $62.05 and a 200 day moving average of $64.14.

Parexel International Corp. (NASDAQ:PRXL) last issued its quarterly earnings data on Wednesday, October 26th. The company reported $0.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.86 by $0.10. The firm had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $525.15 million. Parexel International Corp. had a return on equity of 30.71% and a net margin of 7.09%. The business’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.70 EPS.

Several large investors have recently modified their holdings of the stock. Eqis Capital Management Inc. raised its stake in shares of Parexel International Corp. by 21.9% in the second quarter. Eqis Capital Management Inc. now owns 5,098 shares of the company’s stock worth $321,000 after buying an additional 916 shares during the period. Capstone Asset Management Co. raised its stake in shares of Parexel International Corp. by 14.2% in the second quarter. Capstone Asset Management Co. now owns 5,949 shares of the company’s stock worth $374,000 after buying an additional 740 shares during the period. Dalton Greiner Hartman Maher & Co. bought a new stake in shares of Parexel International Corp. during the second quarter worth about $15,012,000. Cryder Capital Partners LLP raised its stake in shares of Parexel International Corp. by 21.7% in the second quarter. Cryder Capital Partners LLP now owns 148,906 shares of the company’s stock worth $9,363,000 after buying an additional 26,533 shares during the period. Finally, Creative Planning raised its stake in shares of Parexel International Corp. by 1.9% in the second quarter. Creative Planning now owns 8,247 shares of the company’s stock worth $519,000 after buying an additional 150 shares during the period. Institutional investors and hedge funds own 96.13% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2016/11/24/q3-2017-earnings-forecast-for-parexel-international-corp-prxl-issued-by-jefferies-group.html.

Parexel International Corp. Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.

5 Day Chart for NASDAQ:PRXL

Receive News & Stock Ratings for Parexel International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parexel International Corp. and related stocks with our FREE daily email newsletter.